The enigma of sepsis
Top Cited Papers
- 15 August 2003
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 112 (4) , 460-467
- https://doi.org/10.1172/jci200319523
Abstract
Sepsis remains a serious cause of morbidity and mortality, and the pathophysiology of the disease is not clear. The definition of the clinical manifestations of sepsis is ever evolving. This review discusses the search for effective therapeutic interventions, hurdles in translational sepsis research, and new therapies in development in current clinical trials.Keywords
This publication has 73 references indexed in Scilit:
- Induction of MIF synthesis and secretion by tubular epithelial cells: A novel action of angiotensin IIKidney International, 2003
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003
- Assessing the Use of Activated Protein C in the Treatment of Severe SepsisNew England Journal of Medicine, 2002
- An Economic Evaluation of Activated Protein C Treatment for Severe SepsisNew England Journal of Medicine, 2002
- C5a receptor and thymocyte apoptosis in sepsisThe FASEB Journal, 2002
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992
- The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculaturein vitro andin vivoInflammation Research, 1991
- Tumor Necrosis Factor and Interleuktn-1 in the Serum of Children with Severe Infectious PurpuraNew England Journal of Medicine, 1988
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationNew England Journal of Medicine, 1988
- Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage.Journal of Clinical Investigation, 1978